ARCHIVES

Switching to Tasigna After Gleevec Therapy Can Achieve Deeper Molecular Response

This article is from The Cancer Letter archive.

Vol. 35 No. 12 | December 28, 2012

Download PDF Visit The Full Archive

Related Articles

Monoclonal Antibody Improves AML Response To Therapy

July 26, 2002

Upton Leaning to New Division for Centers, Organ Sites, Education

August 25, 1978

NCAB Committee Still Debating How To Encourage Surgical Oncology

April 26, 1985

In Brief: Comprehensive Designation To MN Center; Bernardin Center Wins NCI Planning Grant

October 16, 1998

NCI Cooperative Group Clinical Trials Approved

July 31, 2009

FCRF Program Proving Good Basic Research Can Be Supported By NCI With a Contract

January 23, 1987